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ABSTRACT 
Objective: Aim of this present study was to prepare and characterize the different polymorphs of Prulifloxacin using Powder X-Ray Diffraction 
analysis (PXRD), Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectrometry (FTIR) 
and dissolution studies.  
Methods: Polymorphs of Prulifloxacin were prepared by cooling crystallization method using various solvents and they exhibited three different 
polymorphic forms that polymorph 1 (P-1), polymorph 2 (P-2) and polymorph 3 (P-3) with acetonitrile, acetone and dichloromethane.  
Results: Rod shaped crystal obtained from acetone (P-2) showed the highest percentage drug release in dissolution study than other crystals due to 
smaller particle size. P-1 form showed higher melting point in thermogram due to more stability. Melting temperatures obtained from DSC graph 
indicate the existence of different crystal forms. Significant differences were found in FTIR studies. Appearance and disappearance of specific peaks 
on the PXRD pattern reveal that the formation of newer crystal forms. 
Conclusion: It was concluded that the Prulifloxacin existed three polymorphic forms and they showed highest solubility and percentage drug 
release than amorphous form.  
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INTRODUCTION  
Prulifloxacin (fig. 1) is chemically, 6-Fluoro-1-methyl-7-[4[(methyl-
2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-1-H,4H-[1, 3]. 
thiazeto (3,2-a) quinoline-3-carboxylic acid. Fluoro quinolones are 
synthetic chemotherapeutic agents that have a broad spectrum of 
antimicrobial activity as well as a unique mechanism of action, 
resulting in inhibition of bacterial DNA gyrase and topoisomerase IV. 
Mostly Prulifloxacin is used in uncomplicated and complicated 
urinary tract infection (UTI), community acquired respiratory tract 
infections, gastroenteritis including infectious diarrhea.  
 
Fig. 1: Chemical structure for Prulifloxacin 
Polymorphism comes from the greek word, Polus=many and 
morph=shape. Thus it is defined as the ability of a substance to exist 
as two or more crystalline phases that have different arrangements 
or conformations of the molecules in crystal lattice.[1] It is well 
recognized that polymorphism and solvate formation affect the 
various pharmaceutically important physicochemical properties, 
such as stability, solubility, dissolution rate, crystal habit (shape), 
tableting behaviour. 
Six polymorphic forms of Pefloxacin were prepared from various 
solvents like methanol, distilled water, ethanol, acetonitrile, 
isopropanol, and DMF [2]. Norfloxacin exist in three polymorphs, it 
was obtained by solvents like acetonitrile, isopropanol and acetone 
[3]. Lomefloxacin showed three polymorphs from solvents like 
water, methanol, and ethanol [4]. Sparfloxacin have two polymorphs 
from water [5]. Levofloxacin exist one pseudopolymorph from water 
[6]. The main objective of this work is to increase the aqueous 
solubility to enhance the absorption, bioavailability and stability of 
the selected drug. In this present work, it was planned to prepare 
different crystal forms of Prulifloxacin using various solvents and to 
characterize them using various instrumental techniques such as 
powder X-ray diffractometry (PXRD), thermal study by differential 
scanning calorimetry (DSC), infra red (IR) spectroscopy, scanning 
electron microscopy (SEM). Since crystal forms may differ in their 
dissolution behavior, it was also planned to study the dissolution 
profile of the prepared crystal forms.  
MATERIALS AND METHODS 
Materials 
Prulifloxacin was obtained from Hetero Drugs, Hyderabad, India. 
The solvents used for crystallization are acetonitrile, acetone, 
dichloromethane and distilled water, which were purchased from S. 
D. Fine Chemicals Ltd, Mumbai, India. 
Preparation of polymorphs by cooling crystallization method  
Solubility of Prulifloxacin drug was checked by adding 5 ml of 
acetonitrile to 0.5 g of drug and known amount of Prulifloxacin (2.5 
g) was added to the above solution. Then 25 ml of acetonitrile was 
added and kept over water bath to reflux for 2 h. After the 
solubilization, the hot solution was slowly cooled to room 
temperature. The solution was filtered and the filtrate was kept at 
room temperature until to form well defined crystals of Prulifloxacin 
(P-1). The obtained crystals were collected by vacuum filtration, 
dried for 24 h in desiccators and stored.  
Other polymorphic forms of Prulifloxacin were prepared by the 
similar method using acetone (P-2) and dichloromethane (P-3).  
Characterization of crystal forms 
Differential scanning calorimetry (DSC)  
The DSC thermo gram was obtained using a DSC-6300SSI Nano Tech 
and the temperature range of scan was set from 100 to 400 °C at a 
rate of 10 °C/min. The sample (50-100 mg) was purged under a flow 
of nitrogen at a flow rate of 50 ml/min. The exact peak temperature, 
melting point and heat of fusion was determined. 
Powder x-ray diffraction (PXRD) 
The powder x-ray diffraction patterns of the samples were recorded 
using a Ricnaku Miniflex 2C. The operating condition was as follows: 
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Target, cu, voltage 40kV, current 30 mA, receiving slit,0.3 mm, preset 
time, 0.60 s, scan speed 10 (deg/min), sampling pitch 0.1 °. The 
divergent slit and scatter slit 1o and auto slit were not used. 
Fourier transforms infrared spectrometry (FTIR spectra) 
The FTIR spectra of prepared crystals was recorded on a double 
beam IR spectrometer (Shimadzu) using the potassium bromide 
disk technique in the range of 400-4000 cm-1. No polymorphic 
changes were observed to be induced by grinding or compressing 
Prulifloxacin raw material for sample preparation. 
Solubility measurement 
Each prepared crystal was weighed individually about 100 mg and 
placed in a 100 ml Erlenmeyer flask with a stopper. Phosphate 
buffer pH 6.8 was added in each flask and mechanically shaken at a 
rate of 80 strokes min-1 for 20 h. An aliquot (1 ml) of each solution 
was withdrawn and filtered through a 0.45 m Millipore filter. The 
solubility of each polymorphic form was determined by 
measurement of the absorbance at 272 nm using UV 
spectrophotometer. 
Scanning electron microscopy (SEM) 
Scanning electron microscopy study was performed to characterize 
the surface morphology or the crystals. The morphology of various 
crystals was investigated by the use of a Jeol JSM-6100 instrument. 
The samples were mounted on a metal stub with an adhesive and 
coated under vacuum with gold. 
Dissolution study  
The in-vitro dissolution study was carried out using eight stations of 
LAB INDIA DISSO 2000 dissolution test apparatus. The samples of 
crystals (100 mg) was prepared by direct compression and will be 
placed in the dissolution medium of phosphate buffer (pH 6.8) at 
37±2 °C with a constant speed of agitation at 100 rpm using USP 
type II (paddle). The fixed volume (1 ml) of the sample was 
withdrawn (with replacement) at 15, 30, 45, 60, 120 and 240 min 
time intervals and diluted approximately. The percentage drug 
release was determined by VU spectroscopy method using 272 nm.  
Stability studies 
Accelerated stability study of these three crystals was carried out as 
per the ICH guidelines [7]. The stability samples were (n=3) kept at 
40±2 °C and 75±5% RH in stability testing chamber (LabTop 
Mumbai, India) for a period of 30, 60, 90 d. After completion of 
above said period, samples were taken out and analyzed for drug 
content. 
RESULTS AND DISCUSSION 
Differential scanning calorimetry 
The DSC curves (fig. 2) of all prepared crystal form showed 
endothermic peaks at 224.01 °C, 226.43 °C, 222.33 °C and 220.91 °C 
for amorphous form of drug P-0, crystals of P-1, P-2 and P-3 
respectively. The exothermic peaks were obtained at 268.37 °C, 
266.78 °C, 267.74 °C, 265.33 °C for P-0, P-1, P-2 and P-3 respectively. 
From endothermic peaks obtained in the DSC curves of crystalline 
forms of Prulifloxacin, they differ in the melting point from an 
amorphous form which indicated that each form exhibited different 
crystalline form with characteristic crystal surface. Higher melting 
point (from endothermic peak) of the P-1 form of polymorph 




Fig. 2: DSC graphs for Prulifloxacin (P-0) and its polymorphs (P-
1, P-2, P-3) 
 
Table 1: X-ray diffraction data for Prulifloxacin (P-0) and its polymorphs (P-1, P-2, P-3) 
P-0 P-1 P-2 P-3 
2θ I% 2θ I% 2θ I% 2θ I% 
6.99 218 11.90 303 11.20 40 11.30 82 
8.65 40 12.40 301 11.50 84 11.70 193 
13.80 68 14.11 163 14.50 89 14.06 216 
15.29 160 15.18 52 15.10 57 15.16 57 
18.66 198 18.60 48 19.24 17 18.57 80 
22.46 44 22.90 273 22.78 179 22.90 415 
27.76 212 27.00 189 27.30 73 27.60 117 
30.63 171 31.00 43 30.33 59 31.20 25 
33.96 173 33.89 127 33.00 26 33.77 112 
37.80 73 37.82 114 37.56 38 38.92 25 
39.18 45 40.43 47 38.00 18 40.21 44 
43.70 44 44.82 43 43.40 23 43.61 44 
45.07 55 45.78 82 45.78 24 45.61 36 
49.86 40 51.01 104 49.03 18 49.75 31 
55.42 40 55.32 46 54.73 19 50.95 25 
58.42 59 58.46 66 58.19 23 58.24 41 
77.50 64 77.44 55 77.38 119 77.44 94 
 
X-ray powder diffraction 
It showed different distinction in the position of the peak (table 1), 
clearly indicating different crystal lattice. The presence of new peaks 
at 11.90 °, 31.00 ° and 51.01 ° in P-1 made it different from the 
commercial sample. A few additional peak also appeared in P-2 (at 
11.20 °, 19.24 ° and 38.00 °) and in P-3 (at 31.20 °, 38.92 ° and 50.95 °) 
suggesting them to be new crystalline forms. Besides the difference 
in the position of 2θ values, the peak intensity counts were also 
different in all the forms. All these forms showed well resolved 
diffraction patterns with various characteristic peaks, hence it 
confirmed that the polymorph of Prulifloxacin P-1, P-2 and P-3 (fig. 
Ganeshan et al. 
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3) were properly obtained. Appearance and disappearance of some 
peaks on the XRD spectrum represented the complete formation of 
crystals of P-1, P-2, P-3 with different crystal lattice from amorphous 
form which was successively achieved by cooling crystallization method. 
 
 
Fig. 3: X-ray patterns for Prulifloxacin (P-0) and its polymorphs (P-1, P-2, P-3) 
 
 
Fig. 4: Comparison of IR spectrum of crystals (P-1, P-2, P-3) with 
amorphous form P-0 
 
Fourier transforms infrared spectrometry (FT-IR spectra) 
The IR Spectra of the three crystal forms were presented in fig. 4. 
The strong bands due to C-F stretching were appeared between 
1250 and 1100 cm-1. The peaks of crystals of P-1, P-2, P-3 showed at 
1157.33, 1130.32, 1118.75 cm-1 respectively. The N-H stretching 
showed the peaks ranges from 1400-1300 cm-1 and P-1, P-2, P-3 
showed peaks at 1348.29, 1377.72, 1386.16 cm-1. There was not 
much significant difference in the absorption band due to N-H 
stretching vibration. The broad bands of COOH group have peaks in 
range of 3000-2800 cm-1and peaks for P-1, P-2, P-3 appeared at 
2976.26, 2972.40, 2762.16 cm-1. From IR spectrum of amorphous 
and polymorphs, it revealed that there was no alteration in the 
characteristic peaks of functional groups which indicated there was 
no interaction between the drug and solvents during the 
crystallization process. 
Solubility 
The solubility values of the three forms of P-1, P-2, P-3 were 0.65, 
0.85, 0.50 mg/ml respectively. The differences in solubility of the 
three forms were due to their different polymorphic nature and this 
study revealed that P-2 form has more solubility. 
Scanning electron microscopy 
SEM photographs of three polymorphic forms of Prulifloxacin were 
shown in fig. 5. These clearly demonstrated the difference in the 
morphology of each crystalline form. P-1, P-2 and P-3 crystals were 
plate, rod or needle and prismatic shaped particles respectively which 
clearly indicating the formation of different typed crystals. The particles 
present in the pure drug have irregular shape and also have smaller 
particle size. Based on the photographs obtained from scanning electron 
microscopy, homogeneity has observed in the surface of each crystalline 
form with different particle size. The formation of regularly shaped 
particles of each crystalline form indicated that the amorphous form has 
been converted in to polymorphs. 
Dissolution studies 
Fig. 6 showed the dissolution profile of all the three crystalline forms 
and amorphous form in pH 6.8 buffer solution. After 240 min, the 
cumulative percentage drug release of each form was calculated by 
the use of calibraion graph obtained at 272 nm (fig. 7). Increasing 
order of drug release was as follows P0<P3<P1<P2, the values of % 
drug release were 51.06%, 58.40%, 72.80%, and 89.40% 
respectively. Due to more solubility of P-2 form showed highest 
percentage drug release. From solubility and dissolution studies, 
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polymorph (P-2) obtained from acetone showed highest cumulative 
percentage drug release when compared to others. 
 
 
Fig. 5: SEM photographs of Prulifloxacin (P-0) and its 
polymorphs (P-1, P-2, P-3) 
 
Stability studies 
All the crystals were screened for accelerated stability studies and 
did not show any physical changes during the study period. The drug 
content were observed (n=3) for all the crystals and results were 
tabulated in table 2, hence they were quite stable at accelerated 
storage conditions. The stability of each crystalline form was proved 
by determining the percentage content under the above said an 
accelerated storage condition. Values nearly 100 % indicated that all 
the polymorphic forms were stable without any alteration on the 
physical characters. 
 
Fig. 6: Graph for comparative dissolution study data  
(P-0 =amorphous form, P-1 = polymorph 1, P-2 = polymorph 2, 
P-3 = polymorph-3) (*n=4) 
 
 
Fig. 7: Standard graph for Prulifloxacin (λ max at 272 nm) 
 
Table 2: Stability studies data 
Crystal forms Percentage drug content* (%) 
After 30 days After 60 days After 90 days 
P-1 99.35±0.2291 98.94±0.4007 98.69±0.2651 
P-2 99.42±0.1553 98.86±0.1652 98.38±0.1997 




The drug was found to exist in three forms depending upon the 
crystallizing solvents. All the results obtained from different studies 
can be very well correlated for all forms prepared. The Prulifloxacin 
crystals obtained from solutions with acetonitrile, acetone, and 
dichloromethane have the polymorphic form of P-1, P-2, and P-3. 
The solubility, PXRD, IR, DSC, SEM and dissolution rates of the 
different polymorphic forms were differed in their studies. It was 
concluded that all the polymorphic forms were stable and they had 
more solubility and percentage drug release than pure form, hence it 
may leads to enhance the absorption and bioavailability of drug. If 
this process can be scaled up to pre-clinical study for further to 
develop in to an invaluable technology in future. 
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